Interpace Biosciences, Inc. (IDXG): Price and Financial Metrics

Interpace Biosciences, Inc. (IDXG): $2.44

-0.13 (-5.06%)

POWR Rating

Component Grades













IDXG Stock Summary

  • With a market capitalization of $20,872,235, Interpace Biosciences Inc has a greater market value than only 3.33% of US stocks.
  • Interpace Biosciences Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 4.06% of US listed stocks.
  • IDXG's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 4.68% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Interpace Biosciences Inc, a group of peers worth examining would be LODE, DUOT, LXFR, KIDS, and CCF.
  • IDXG's SEC filings can be seen here. And to visit Interpace Biosciences Inc's official web site, go to

IDXG Valuation Summary

  • IDXG's price/earnings ratio is -1.7; this is 104.66% lower than that of the median Healthcare stock.
  • Over the past 243 months, IDXG's price/sales ratio has gone up 0.4.
  • Over the past 243 months, IDXG's price/sales ratio has gone up 0.4.

Below are key valuation metrics over time for IDXG.

Stock Date P/S P/B P/E EV/EBIT
IDXG 2021-08-31 1.0 -1.0 -1.7 -2.1
IDXG 2021-08-30 1.0 -1.0 -1.7 -2.1
IDXG 2021-08-27 1.0 -1.1 -1.7 -2.1
IDXG 2021-08-26 1.0 -1.0 -1.7 -2.1
IDXG 2021-08-25 1.0 -1.0 -1.7 -2.1
IDXG 2021-08-24 0.9 -1.0 -1.7 -2.0

IDXG Growth Metrics

    Its year over year net cashflow from operations growth rate is now at 48.69%.
  • Its 3 year cash and equivalents growth rate is now at 110.23%.
  • Its 3 year price growth rate is now at -69.14%.
IDXG's revenue has moved up $17,008,000 over the prior 30 months.

The table below shows IDXG's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 40.106 -9.085 -19.357
2021-06-30 38.882 -14.131 -22.03
2021-03-31 33.173 -11.863 -24.164
2020-12-31 32.398 -13.979 -29.484
2020-09-30 26.968 -18.796 -32.434
2020-06-30 26.445 -17.845 -33.637

IDXG Price Target

For more insight on analysts targets of IDXG, see our IDXG price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.43 Average Broker Recommendation 1.5 (Moderate Buy)

IDXG Stock Price Chart Interactive Chart >

Price chart for IDXG

IDXG Price/Volume Stats

Current price $2.44 52-week high $10.33
Prev. close $2.57 52-week low $1.67
Day low $2.42 Volume 3,487
Day high $2.71 Avg. volume 9,778
50-day MA $3.00 Dividend yield N/A
200-day MA $5.30 Market Cap 10.32M

Interpace Biosciences, Inc. (IDXG) Company Bio

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

IDXG Latest News Stream

Event/Time News Detail
Loading, please wait...

IDXG Latest Social Stream

Loading social stream, please wait...

View Full IDXG Social Stream

Latest IDXG News From Around the Web

Below are the latest news stories about Interpace Biosciences Inc that investors may wish to consider to help them evaluate IDXG as an investment opportunity.

Interpace Biosciences Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid Tests

PARSIPPANY, NJ, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, announced today that the National Correct Coding Initiative (NCCI) program issued a response on behalf of the Centers for Medicare & Medicaid Services (CMS) stating that the previously announced billing policy reimbursement for its ThyGeNEXT (O245U) and ThyraMIR (oo18U) tests, disclosed by it in a press release dated January 28, 2

Yahoo | February 22, 2022

Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests

PARSIPPANY, NJ, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”) a leader in enabling personalized medicine, announced today that it was terminating its previously announced rights offering and the mutual termination of the standby purchase agreement with 3K Limited Partnership. Interpace also announced that it just became aware that the Centers for Medicare & Medicaid Services (CMS) issued a new billing policy whereby CMS will no longer

Yahoo | January 29, 2022

Interpace Biosciences Announces Appointment of Vijay Aggarwal, Ph.D. as New Director

PARSIPPANY, NJ, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences , Inc. (OTCQX: IDXG) (“Interpace”) a leader in enabling personalized medicine, is pleased to announce today that Vijay Aggarwal, Ph.D., has been appointed to the Interpace Board of Directors effective February 1, 2022. Dr. Aggarwal replaces Eric B. Lev, both designees of Ampersand 2018 Limited Partnership, a Series B Preferred stockholder of the Company. Dr. Aggarwal has over thirty years of experience in both pharmaceutical

Yahoo | January 27, 2022

Interpace Biosciences begins $30M rights offering

Interpace Biosciences (IDXG) began its previously announced fully back-stopped rights offering of up to $30M

Seeking Alpha | January 12, 2022

Interpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights Offering

PARSIPPANY, NJ, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it commenced its previously announced fully back-stopped Rights Offering of up to $30 million. Under the terms of the Rights Offering, the Company is distributing non-transferable subscription rights to each holder of its common stock as well as to each holder of its outstanding warrants to purchase common stock in each case held as of 5:00 p.m. Eastern

Yahoo | January 12, 2022

Read More 'IDXG' Stories Here

IDXG Price Returns

1-mo -9.63%
3-mo -31.27%
6-mo -50.20%
1-year -72.89%
3-year -67.02%
5-year -69.50%
YTD -67.34%
2021 137.90%
2020 -37.20%
2019 -37.50%
2018 -21.57%
2017 -76.82%

Continue Researching IDXG

Want to see what other sources are saying about Interpace Biosciences Inc's financials and stock price? Try the links below:

Interpace Biosciences Inc (IDXG) Stock Price | Nasdaq
Interpace Biosciences Inc (IDXG) Stock Quote, History and News - Yahoo Finance
Interpace Biosciences Inc (IDXG) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6205 seconds.